PMID- 20578967
OWN - NLM
STAT- MEDLINE
DCOM- 20110218
LR  - 20161018
IS  - 1437-4331 (Electronic)
IS  - 1434-6621 (Linking)
VI  - 48
IP  - 10
DP  - 2010 Oct
TI  - Serum soluble tumour necrosis factor receptor type I concentrations independently 
      predict prognosis in patients with breast cancer.
PG  - 1481-6
LID - 10.1515/CCLM.2010.278 [doi]
AB  - BACKGROUND: The aim of this study was to exploit the potential clinical use of 
      circulating cytokine assessment in patients with breast cancer. METHODS: The 
      following circulating cytokines were measured in 210 histopathologically 
      confirmed, untreated breast cancer patients: interleukin 6 (IL-6), tumour 
      necrosis factor-alpha (TNFalpha), interleukin 8 (IL-8), soluble tumour necrosis factor 
      receptor type I (sTNF RI), sTNF RII, interleukin 1 receptor antagonist (IL-1ra), 
      interleukin 10 (IL-10), macrophage colony-stimulating factor, vascular 
      endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). The 
      patients have been followed-up for 10 years. RESULTS: bFGF and VEGF showed the 
      highest diagnostic sensitivity. Only IL-6 concentrations were related to the 
      clinical stage. A high percentage of patients in clinical stage I showed 
      increased serum sTNF RII, VEGF and bFGF concentrations, of which only sTNF RII 
      was found to be increased in a smaller percentage of patients with more advanced 
      disease compared with patients with early stage disease. Patients aged 50 years 
      and more presented with significantly higher concentrations of sTNF RI, IL-10, 
      IL-6 and VEGF compared with younger patients. In multivariate analysis, a 
      significant value of pretreatment serum sTNF RI concentrations, next to stage and 
      oestrogen receptors status, was its utility as an independent prognostic factor 
      of the overall survival in patients with breast cancer. CONCLUSIONS: Serum sTNF 
      RI may be considered an additional, independent and clinically useful factor of 
      poor prognosis in patients with breast cancer.
FAU - Fuksiewicz, Malgorzata
AU  - Fuksiewicz M
AD  - Department of Tumour Markers, Maria Sklodowska-Curie Cancer Centre and Institute 
      of Oncology, Warsaw, Poland. fuksiewiczm@coi.pl
FAU - Kowalska, Maria
AU  - Kowalska M
FAU - Kotowicz, Beata
AU  - Kotowicz B
FAU - Rubach, Maryna
AU  - Rubach M
FAU - Chechlinska, Magdalena
AU  - Chechlinska M
FAU - Pienkowski, Tadeusz
AU  - Pienkowski T
FAU - Kaminska, Janina
AU  - Kaminska J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100627
PL  - Germany
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine
JID - 9806306
RN  - 0 (Cytokines)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type I)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*blood/*diagnosis
MH  - Cytokines/blood
MH  - Female
MH  - Fibroblast Growth Factor 2/blood
MH  - Follow-Up Studies
MH  - Humans
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Receptors, Tumor Necrosis Factor, Type I/*blood
MH  - Sensitivity and Specificity
MH  - Solubility
MH  - Survival Analysis
MH  - Vascular Endothelial Growth Factor A/blood
EDAT- 2010/06/29 06:00
MHDA- 2011/02/22 06:00
CRDT- 2010/06/29 06:00
PHST- 2010/06/29 06:00 [entrez]
PHST- 2010/06/29 06:00 [pubmed]
PHST- 2011/02/22 06:00 [medline]
AID - 10.1515/CCLM.2010.278 [doi]
PST - ppublish
SO  - Clin Chem Lab Med. 2010 Oct;48(10):1481-6. doi: 10.1515/CCLM.2010.278. Epub 2010 
      Jun 27.